LENZ Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed November 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
RA Capital Management, L.P. (Boston-based investment firm) filed an amended Schedule 13D/A for LENZ Therapeutics, Inc. on November 2, 2026. The filing document itself contains no accessible details on the specific amendment content, share counts, ownership percentages, or transaction amounts due to format limitations in the SEC filing submission.
Why this rating
Schedule 13D amendments are routine disclosure updates; absent concrete specifics on ownership changes, this appears administrative rather than material to ~$690M market cap.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.